Cargando…

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors

INTRODUCTION: Fibroblast growth factor receptor (FGFR)-4/FGF19 pathway dysregulation is implicated in hepatobiliary and other solid tumors. INCB062079, an oral, selective, FGFR4 inhibitor, inhibits growth in FGF19/FGFR4-driven liver cancer models. METHODS: This was a two-part, phase I study (NCT0314...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harding, James J., Jungels, Christiane, Machiels, Jean-Pascal, Smith, David C., Walker, Chris, Ji, Tao, Jiang, Ping, Li, Xin, Asatiani, Ekaterine, Van Cutsem, Eric, Abou-Alfa, Ghassan K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042765/ https://www.ncbi.nlm.nih.gov/pubmed/36787089 http://dx.doi.org/10.1007/s11523-023-00948-8

Ejemplares similares

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
por: Liu, Phillip C. C., et al.
Publicado: (2020)

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
por: Lacouture, Mario E., et al.
Publicado: (2020)

The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
por: Leal, Ana S., et al.
Publicado: (2020)

IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma
por: Buhe, Hada, et al.
Publicado: (2022)

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression
por: Deng, Manman, et al.
Publicado: (2023)

Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa
por: Abou-Alfa, Ghassan
Publicado: (2020)

Suppression and Regression of Choroidal Neovascularization in Mice by a Novel CCR2 Antagonist, INCB3344
por: Xie, Ping, et al.
Publicado: (2011)

INCB, WHO AND UNODC STATEMENT ON ACCESS TO INTERNATIONALLY CONTROLLED MEDICINES DURING COVID-19 PANDEMIC
Publicado: (2020)

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies
por: Koblish, Holly, et al.
Publicado: (2018)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017)

Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies
por: Alavi, Afsaneh, et al.
Publicado: (2022)

ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2010)

Global Oncology Medical Diplomacy Working Group Inaugural Meeting: Defining Worldwide Barriers to Germline Genomics in Cancer Prevention and Management
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2023)

Treatment options after sorafenib failure in patients with hepatocellular carcinoma
por: Dika, Imane El, et al.
Publicado: (2017)

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
por: Martin-Liberal, Juan, et al.
Publicado: (2020)

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
por: Gangadhar, Tara C, et al.
Publicado: (2015)

A hybrid design for dose‐finding oncology clinical trials
por: Liao, Jason J. Z., et al.
Publicado: (2022)

Hepatocellular carcinoma, novel therapies on the horizon
por: El Dika, Imane, et al.
Publicado: (2020)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
por: Ji, Jun Ho, et al.
Publicado: (2023)

P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS
por: Bose, Prithviraj, et al.
Publicado: (2023)

Discovery of Gastric Metastases From Primary Renal Cell Carcinoma Through MRI: A Case Report
por: Saifi, Adrien, et al.
Publicado: (2023)

Differential expression of groEL-1, incB, pyk-F, tal, hctA and omcB genes during Chlamydia trachomatis developmental cycle
por: Mzobe, Gugulethu F., et al.
Publicado: (2021)

Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma
por: Chami, Perla, et al.
Publicado: (2023)

Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer
por: Schmitz, Sandra, et al.
Publicado: (2015)

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
por: Le Tourneau, Christophe, et al.
Publicado: (2020)

P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
por: Watts, Justin M., et al.
Publicado: (2023)

Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma
por: Costa, Frederico, et al.
Publicado: (2023)

The Chemokine (C-C Motif) Receptor 2 Antagonist INCB3284 Reduces Fluid Requirements and Protects From Hemodynamic Decompensation During Resuscitation From Hemorrhagic Shock
por: DeSantis, Anthony J., et al.
Publicado: (2022)

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response
por: Bibeau, Kristen, et al.
Publicado: (2022)

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
por: Springuel, Lorraine, et al.
Publicado: (2019)

Trabectedin-Related Heart Failure: Case Report and a Systematic Review of the Literature
por: Catherine, Julien, et al.
Publicado: (2021)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review
por: Agrafiotis, Apostolos C., et al.
Publicado: (2023)

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2022)

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
por: Koyama, Takafumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r88rsmilau6jr930gsl0kli84p